LIPOSOMAL DRUG DELIVERY SYSTEM: AN OVERVIEW (original) (raw)

2022, Shodhasamhita : Journal of Fundamental & Comparative Research

Liposomes were the first nanoscale drug to be approved for clinical use in 1995.A major advancement in liposome-based delivery methods has been made since that time, and these advancements have important therapeutic consequences. For example, this comprises liposomes that can remain in the body for a lengthy period of time, liposomes that can be nebulized and elastic liposomes that can be used for topical, oral, and transdermal distribution. In contrast to liposomes, existing guidance on novel delivery strategies has not been well-documented. Liposomal delivery systems are described in detail, along with the regulatory landscape surrounding commercialization efforts for higher-level complexity systems, expected requirements, and obstacles faced by companies looking to bring novel liposome-based systems to market for clinical use, in this in-depth assessment.